NAPA, California, April 17 /PRNewswire/ --

Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced it has engaged Riley-Nacht LLC, a global brand development and marketing company focused on the skincare industry to support the commercialization of Senetek's dermatological products.

Riley-Nacht was founded by Les Riley, Dr. Sergio Nacht and Brian Riley. Riley-Nacht is known for their expertise in all phases of brand development and will play a key role in Senetek's dermatological product marketing program.

Les Riley stated, "Pyratine-6(TM) is a next generation skin care technology. Based on a review of the clinical data, we are enthusiastic about working with Senetek on its commercial development. Pyratine-6(TM) has the potential for extraordinary success in the global skin care markets."

Les Riley has over thirty years of experience in the pharmaceutical and skincare industries. Prior to founding Riley-Nacht, Mr. Riley was President of Cardinal Health, Topical Technologies, a company formed through the acquisition of Advanced Polymer Systems that integrated existing Cardinal Health technologies and infrastructure. Mr. Riley has also served as President and CEO of TriStrata Incorporated, and President and CEO of NeoStrata Company Inc., a subsidiary of TriStrata. Mr. Riley spent seventeen years with Johnson & Johnson Co., Inc. as President of the Dermatological Division, where he was responsible for operations, including sales and marketing, licensing and acquisitions, and new product development.

Mr. Riley was granted membership in the American Academy of Dermatology in 2004, in recognition of his years of service and contribution to advancing the specialty of dermatology.

Dr. Sergio Nacht is a skin biologist with 35 years of academic, industrial and commercial experience. Prior to the founding of Riley-Nacht, Dr. Sergio Nacht was Senior Vice President of Dermatology and Skin Care at Cardinal Health, Topical Technologies, where he was responsible for the overall expansion of Topical Technologies with emphasis on dermatological and skincare technologies and for technical business development worldwide. Dr. Nacht also occupied key scientific and R&D positions at Richardson-Vicks/ Procter & Gamble and at Alza Corporation.

Dr. Nacht is a member of several professional societies, including the American Academy of Dermatology, The Dermatology Foundation and The Society of Cosmetic Chemists. He has co-authored more than 50 scientific papers and book chapters and holds fifteen U.S. patents.

Brian Riley has over ten years experience in the sales, marketing and distribution of skin and personal health products. Mr. Riley created and developed Boulder Consulting, a marketing firm focused on business planning, marketing, and product development for clients in the skincare industry including Boston University, Department of Dermatology, and Rejuvenation Centers, Ltd.

Prior to founding Boulder Consulting, Mr. Riley partnered with leading executives in the industry to form DermFirst Inc., with clients including Ortho-Neutrogena, Allergan Skincare, ICN Pharmaceuticals, ProCyte, Inc., Genesis Pharmaceutical, and NeoStrata Company. Mr. Riley was also involved in the development of an anti-aging treatment system marketed through direct response television.

As a marketer, Mr. Riley had responsibility at Medicis Pharmaceutical Corporation for the launch and overall management of TxSystems, a new business unit specializing in non-prescription dermatologicals for improving the appearance of aging skin. Mr. Riley was also involved in the launch and/or marketing of the Medicis prescription and OTC products, including Lustra(R), Esoterica(R), Dynacin(R), Triaz(R), Novacet(R), Loprox(R), Lidex(R), and Synalar(R).

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "The team of Riley and Nacht bring unparalleled expertise to our program for the accelerated development of Senetek's substantial dermatological portfolio. Their extensive networks and affiliations with current thought leaders in dermatology will help define the course of our marketing efforts in this area."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Web site: http://www.senetekplc.com

Marjorie Hays, Vice President, Communications of Senetek PLC, +1-707-226-3900, ext. 102